

Supplementary Table 1 Clinical features of 38 SSc patients with foot ulcers

Ref.	Year	Country	Age	Gender	SSc specific antibody	R P	Ulcer localization	Ulcer duration	Lower extremity arterial stenosis or occlusion	Failed treatments	Effective systemic treatments	Effective local treatments	Healing	Time to healing
Abignano et al[1]	2020	UK	72	F	ACA	Yes	Left hallux and pelma	NA	Yes	NA	Antibiotics, iloprost, oxycodone, and naloxone	Chloramphenicol, collagenase ointments, and a silver	Yes	NA

												dressing containing alginate		
Appel <i>et al</i> [2]	1997	Germany	63	F	ACA	Yes	Right hallux s	NA	Yes	Percutaneous transluminal angioplasty	Iloprost, CTX, and analgetic medication	NA	Yes	NA
Balbir-Gurman <i>et al</i> [3]	2007	Israel	63	F	NA	Yes	The fifth toe of right foot	Several weeks	Yes	LMWH, aspirin, antibiotics, and ilomedin	Adrenalectomy (pheochromocytoma)	NA	Yes	3 months
Boey[4]	2020	Singapore	71	F	NA	NA	Right foot	NA	Yes	NA	NA	Plain balloon	old Yes	3 months

						dorsal						angioplasty, Natrox® Oxygen wound therapy, and two-layer compression bandaging	hs	
Garri do- Ríos <i>et al</i> [5]	2018	Spain	30	F	Anti-Scl-70 antibody	Y	Both heel, the toes of the right foot, and the	6 months	NA	NA	Antibiotics and fentanyl	Antibiotics, silicone and foam dressings, ibuprofen, tetracaine, and BTX	NA	NA

							hallux, fourth and fifth toes of the left foot							
Hoss einial hashe mi et al[6]	201 7	Iran	43	F	NA	Y	Left foot	3 weeks	NA	NA	NA	Amputatio n below the knee	Yes	NA
Huh et al[7]	202 1	Amer ican	54	M	NA	Y	The second toe of left foot	NA	NA	Sildenafi l with shoe modifica tion, padding,	Bosentan	Debridem ent and hammertoe deformity corrections	Yes	3 week s

											and wound care				
Kwon et al[8]	2009	Korea	42	F	NA	Yes	The fourth toe of right foot	NA	Yes	NA	NA	Bypass surgery	Yes	28 months	
Kanamaru et al[9]	2015	Japan	75	F	ACA	NA	Right hallux, second and little toes	NA	NA	Amputation below the right knee	NA	Platelet-rich plasma therapy and a full-thickness skin graft	Yes	1.5 months	
Khaliq et al	2023	Syria	81	F	Anti-Scl-70	No	Left hallux	NA	No	Methylprednisolone	NA	NA	No (Deceased)	-	

					RNA polym erase III (RP15 5) antibo dy									
Marq ues <i>et</i> <i>al</i> [12]	201 6	Portu gal	78	F	Anti- Scl-70 antibo dy	Y e s	Unilater al toes	NA	Yes	Enoxapa rin, prostano id, sildenafil, aspirin, sinvastat in and	NA	Amputatio n below the knee	Yes	NA

										PTX				
			76	F	Anti-Scl-70 antibody	Yes	Unilateral toes	NA	Yes	Enoxaparin, prostano id, sildenafil, aspirin, sinvastatin and PTX	NA	Amputation below the knee	No (death)	-
Matsuura-otsuki <i>et al</i> [13]	2016	Japan	72	F	ACA	NA	The second toe of right foot	8 months	Yes	Antihypertensive s, antiplatelet agents	NA	Bypass surgery	Yes	1 month

											and endothel in receptor blockers				
Miras oglu et al[14]	201 7	Turk ey	62	F	NA	N A	Right toe	12 month s	NA	NA	Immunosu ppressor and antibiotics	Hyperbari c oxygen, hydrofiber silver, debrideme nt	Yes	NA	
Naert et al[15]	201 3	Belgi um	48	M	Anti- Scl-70 antibo dy	Y e s	The left hallux, and inner and outer left	6 month s	No	Amnioti c membra ne transpla ntation,	Antibiotic, prostanoid s, LMWH, and bosentan	Silver foam dressings	Yes	6 mont hs (hallu x)	

ankle

keratino

cyte

grafts,

silver

foam

dressing

s,

dihydro

pyridine

-type

calcium

antagoni

st,

aspirin,

and

simvasta

tin

Pauli ng et al[16]	201	UK	91	F	ACA	Yes	Right hallux	6 years	Yes	Iloprost, antibioti c, larval therapy, surgical debride ment, and peroneal artery balloon angiopla sty	Bosentan	Amputatio n of hallux	Yes	NA
Poirie r et al[17]	201	Franc e	48	F	Anti- Scl-70 antibo dy	Yes	The fourth toe of left foot	NA	No	NA	Bosentan and diltiazem	Hyperbari c oxygen therapy, vaseline	Yes	8 mont hs

													dressing		
Quintana Castañedo et al[18]	2020	Spain	15	F	ACA	Y	Both e hallux s	4 months	NA	Nifedipine and bosentan	NA	BTX, lidocaine/prilocaie 5% cream (EMLA®)	Yes	4 weeks	
Saigués et al[19]	2021	Japan	73	F	ACA	Y	Right e foot s dorsal and left crus inside	3 years	NA	NA	NA	NA	No(d eath)	-	
Sant et al[20]	1994	Ireland	60	M	NA	Y	The first e metatars ophalan geal joint	2 months	NA	NA	NA	NA	NA	NA	

							of the							
							left foot							
Stein <i>et al</i> [21]	2017	Germ any	69	NA	Anti-Pm-Scl antibody	N A	Righat foot dorsal	1 year	Yes	NA	NA	Aorto-biiliac stent implantation	Yes	NA
Shanmugam <i>et al</i> [22]	2010	American	NA	M	ACA	N A	Left medial malleolus	Just started	Yes	NA	NA	Arterioplasty	Yes	6 months
			NA	F	ACA	N A	Bilateral malleoli and right posterior ankle	350 months	No	NA	Enoxaparin	NA	No	-
			NA	F	anti-	N	Bilateral	7	No	NA	Enoxaparin	NA	Yes	3

			RNA	A	malleoli	month			stopped			mont
			polym			s			due to			hs
			erase						bleeding,			
			III						darbepoeti			
			antibo						nalfa			
			dy									
NA	M	No		N	Bilateral	Just	No	NA	Pentoxifylli	NA	Yes	6
				A	toes,	started			ne			mont
					dorsal							hs
					foot and							
					heel							
NA	F	Anti-		N	Right	36	No	NA	Enoxaparin	NA	No	-
		Scl-70		A	medial	month						
		antibo			malleolu	s						
		dy			s, left							
					dorsal							
					foot							

			NA	F	ACA	N	Bilateral	3	No	NA	No	No	No	-
						A	malleoli	month						
							s							
			NA	F	Anti-	N	Left	5	No	NA	NA	Venous	No	-
					Scl-70	A	lateral	month				surgery		
					antibo		malleolu	s						
					dy		s							
			NA	F	ACA	N	Bilateral	3	No	NA	Nifedipine	NA	Yes	3
						A	toes and	month						mont
							bottom	s						hs
							of feet							
Shett	201	India	46	F	NA	N	Left	1 year	NA	non-	NA	Autologou	Yes	3
y and	6					A	hallux			steroidal		s platelet-		mont
Shen										analgesi		rich fibrin		hs
oi[23]										cs,				
										pentoxif				
										ylline,				

											aspirin, proton pump inhibitor and antibioti cs along with regular dressing s				
Sukhi ja et al[24]	202	UK	46	M	No	Y	Left e medial s malleolu s	NA	No	NA	Antibiotics, prednisolo ne and mycophen olate mofetil	NA	NA	NA	NA

Taka hashi <i>et</i> <i>al</i> [25]	199 7	Japan	60	F	ACA	Y e s	Right toes	NA	Yes	NA	NA	NA	NA	NA
Tanig uchi <i>et</i> <i>al</i> [26]	201 2	Japan	45	F	Anti- U1RN P antibo dy	N A	Left heel	6 month s	NA	NA	Bosentan, tocopherol nicotinate, ethyl icosapentat e, beraprost sodium, alprostadil, and algatroban	NA	Yes	4 mont hs

80	F	ACA	N A	Left foot	NA	Yes	NA	Bosentan, tocopherol nicotinate, beraprost sodium, sarpogrelat e, cilostazol, alprostadil, and algotroban	NA	Yes	15 mont hs
69	F	Anti- Scl-70 antibo dy	N A	Both heels	10 years	NA	NA	Bosentan, sarpogrelat e, limaprost alfadex, alprostadil,	NA	No	-

											and			
											algatroban			
			49	F	Anti-	N	Left heel	2	Yes	NA	Bosentan,	NA	Yes	6
					Scl-70	A		month			tocopherol			mont
					antibo			s			nicotinate,			hs
					dy						limaprost			
											alfadex,			
											alprostadil,			
											and			
											algatroban			
Yama	199	Japan	68	F	NA	Y	Right toe	1	Yes	Prostagl	Prednisolo	NA	NA	NA
da et	7					e		month		andin	ne			
al[27]						s				E1,				
										argatrob				
										an,				
										sarpogre				
										late				

hydrochl
oride,
and
urokinas
e

ACA: anti-centromere antibody; anti-Scl-70 antibody: anti-scleroderma-70 antibody; anti-Pm-Scl antibody: anti-Pm-scleroderma antibody; anti-U1RNP antibody: anti-U1 small nuclear ribonucleoprotein antibody; BTX: botulinum toxin; CTX: cyclophosphamide; F: female; LMWH: low molecular weight heparin; M: male; NA: not available; PTX: pentoxifilin; RP: Raynaud's phenomenon.

REFERENCE

- 1 **Abignano G**, Mennillo GA, Lettieri G. Foot ulcers in systemic sclerosis escape surgical amputation. *Lancet* 2020; **396**: e29 [PMID: 32919519 DOI: 10.1016/S0140-6736(20)31896-1]
- 2 **Appel H**, Sieper J, Golder W, Hiepe F, Distler A, Braun J. [Autoantibodies against centrosomes in a patient with limited systemic sclerosis with ulcera cruris and arteriopathy--case report and review of the literature]. *Z Rheumatol* 1997; **56**: 298-305 [PMID: 9465383 DOI: 10.1007/s003930050044]
- 3 **Balbir-Gurman A**, Menahem Nahir A, Rozin A, Markovits D, Braun-Moscovici Y. Toe necrosis and acute myocardial infarction precipitated by a pheochromocytoma in a patient with systemic sclerosis. *J Clin Rheumatol* 2007; **13**: 331-333 [PMID: 18176142 DOI: 10.1097/RHU.0b013e31815c1df8]

- 4 **Boey J**. Arteriovenous foot ulcer. *J Wound Care* 2020; **29**: S24-S25 [PMID: 32427029 DOI: 10.12968/jowc.2020.29.Sup5b.S24]
- 5 **Garrido-Ríos AA**, González-Olivares M, Navarro-Vidal B, Martínez-Morán C, Borbujo J. Ischaemic ulcers on the toes secondary to Raynaud phenomenon in a patient with systemic sclerosis successfully treated with botulinum toxin. *Clin Exp Dermatol* 2018; **43**: 503-505 [PMID: 29274125 DOI: 10.1111/ced.13333]
- 6 **Hosseinihashemi M**, Daneshfard B, Keshavarzian O. Severe Acro-osteolysis in a Case of Limited Cutaneous Scleroderma. *Iran J Public Health* 2017; **46**: 146-147 [PMID: 28451545]
- 7 **Huh J**, Black L, De Blasio DC, Tracy CL, Berry-Cabán CS. Novel Use of Bosentan for Postoperative Wound Healing of the Foot in Systemic Sclerosis. *J Clin Rheumatol* 2021; **27**: S692-S693 [PMID: 33264247 DOI: 10.1097/RHU.0000000000001585]
- 8 **Kwon ST**, Eun SC, Baek RM, Minn KW. Peripheral arterial- bypass grafts in the hand or foot in systemic sclerosis. *J Plast Reconstr Aesthet Surg* 2009; **62**: e216-e221 [PMID: 19217840 DOI: 10.1016/j.bjps.2008.11.080]
- 9 **Kanemaru H**, Kajihara I, Yamanaka K, Igata T, Makino T, Masuguchi S, Fukushima S, Jinnin M, Ihn H. Platelet-rich plasma therapy is effective for the treatment of refractory skin ulcers in patients with systemic sclerosis. *Mod Rheumatol* 2015; **25**: 660-661 [PMID: 24933352 DOI: 10.3109/14397595.2014.924204]
- 10 **Khalayli N**, Ibrahim R, Ibrahim R, Kudsi M. Antineutrophil cytoplasmic antibody-associated vasculitis with systemic sclerosis: a fatal case report. *Ann Med Surg (Lond)* 2023; **85**: 5770-5775 [PMID: 37915665 DOI: 10.1097/MS9.0000000000001347]
- 11 **17th International Congress of Immunology**, 19-23 October 2019, Beijing, China. *Eur J Immunol* 2019; **49 Suppl 3**: 1-2223 [PMID: 31592543 DOI: 10.1002/eji.201970400]

- 12 **Marques B**, Castro SG, Figueiredo I, Magalhaes FG, Antunes M, Gruner H, Panarra A. Management of systemic sclerosis and peripheral arterial disease in the elderly. *Eur Geriatr Med* 2016; **7**: S75
- 13 **Matsuura-Otsuki Y**, Hanafusa T, Namiki T, Ueno M, Inazawa M, Tokoro S, Igawa K, Nakamura M, Igari K, Inoue Y, Yokozeki H. Peripheral arterial bypass surgery for intractable wounds caused by limited cutaneous systemic sclerosis. *J Dermatol* 2016; **43**: 1447-1448 [PMID: 27129608 DOI: 10.1111/1346-8138.13425]
- 14 **Mirasoglu B**, Bagli BS, Aktas S. Hyperbaric oxygen therapy for chronic ulcers in systemic sclerosis - case series. *Int J Dermatol* 2017; **56**: 636-640 [PMID: 28233289 DOI: 10.1111/ijd.13570]
- 15 **Naert A**, De Haes P. Successful treatment with bosentan of lower extremity ulcers in a scleroderma patient. *Case Rep Med* 2013; **2013**: 690591 [PMID: 23653656 DOI: 10.1155/2013/690591]
- 16 **Pauling JD**, Brown SJ, James J, Shipley JA, Korendowych E, McHugh NJ. Vacuum-assisted closure therapy: a novel treatment for wound healing in systemic sclerosis. *Rheumatology (Oxford)* 2011; **50**: 420-422 [PMID: 20959357 DOI: 10.1093/rheumatology/keq319]
- 17 **Poirier E**, Wind H, Cordel N. [Efficacy of hyperbaric oxygen therapy in the treatment of ischemic toe ulcer in a patient presenting systemic sclerosis]. *Ann Dermatol Venereol* 2017; **144**: 55-59 [PMID: 27476378 DOI: 10.1016/j.annder.2016.06.007]
- 18 **Quintana Castanedo L**, Feito Rodríguez M, Maseda Pedrero R, Chiloeches Fernández C, de Lucas Laguna R. Ischemic ulcers of the toes secondary to Raynaud's phenomenon in a child successfully treated with botulinum toxin. *Pediatr Dermatol* 2020; **37**: 681-683 [PMID: 32212180 DOI: 10.1111/pde.14160]

- 19 **Saigusa R**, Toyama T, Ichimura Y, Taniguchi T, Yoshizaki A, Sato S, Asano Y. A Case of Systemic Sclerosis Complicated With Portal Hypertension. *J Clin Rheumatol* 2021; **27**: S668-S669 [PMID: 33264252 DOI: 10.1097/RHU.0000000000001633]
- 20 **Sant SM**, Murphy GM. Neurotropic ulceration in systemic sclerosis. *Clin Exp Dermatol* 1994; **19**: 65-66 [PMID: 8313642 DOI: 10.1111/j.1365-2230.1994.tb01120.x]
- 21 **Stein F**, Kamper L, Meletiadis K, Kusenack U, Haage P. [Advanced Systemic Sclerosis: Endovascular Reconstruction of the Aortic Bifurcation for Limb Salvage]. *Dtsch Med Wochenschr* 2017; **142**: 43-46 [PMID: 28056476 DOI: 10.1055/s-0042-120108]
- 22 **Shanmugam VK**, Price P, Attinger CE, Steen VD. Lower extremity ulcers in systemic sclerosis: features and response to therapy. *Int J Rheumatol* 2010; **2010**: 747946 [PMID: 20827313 DOI: 10.1155/2010/747946]
- 23 **Shetty S**, Shenoi SD. Autologous platelet-rich fibrin in treatment of scleroderma ulcer. *Int Wound J* 2016; **13**: 1065-1066 [PMID: 26290396 DOI: 10.1111/iwj.12480]
- 24 **Sukhija G**, Man YL, Lutalo P, Pollard L, Yanni G. A case of limited cutaneous systemic sclerosis evolving into an overlap syndrome with systemic lupus erythematosus and pyoderma gangrenosum. *Rheumatology Advances in Practice* 2022; **6**: i34-i35
- 25 **Takahashi M**, Okada J, Kondo H. Six cases positive for anti-centromere antibodies with ulcer and gangrene in the extremities. *Br J Rheumatol* 1997; **36**: 889-893 [PMID: 9291859 DOI: 10.1093/rheumatology/36.8.889]
- 26 **Taniguchi T**, Asano Y, Hatano M, Tamaki Z, Tomita M, Kawashima T, Miyazaki M, Sumida H, Akamata K, Takahashi T, Ichimura Y, Toyama T, Sugita M, Noda S, Yao A, Kinugawa K, Sato S. Effects of bosentan on nondigital ulcers in patients with systemic sclerosis. *Br J Dermatol* 2012; **166**: 417-421 [PMID: 21848685 DOI: 10.1111/j.1365-2133.2011.10581.x]

27 **Yamada S**, Kameda H, Hirakata M, Ohosone Y, Mimori T, Ikeda Y. Successful treatment of toe gangrene with moderate-dose steroid therapy in a patient with systemic sclerosis (CREST syndrome). *Ryumachi* 1997; **37**: 499-503.